Document is current
Any future updates will be listed below
-
Authors
Niehrs, Annika https://orcid.org/0000-0002-2190-4346
Garcia-Beltran, Wilfredo F.
Norman, Paul J. https://orcid.org/0000-0001-8370-7703
Watson, Gabrielle M. https://orcid.org/0000-0003-0056-7528
Hölzemer, Angelique
Chapel, Anaïs
Richert, Laura
Pommerening-Röser, Andreas
Körner, Christian
Ozawa, Mikki
Martrus, Glòria
Rossjohn, Jamie https://orcid.org/0000-0002-2020-7522
Lee, Jar-How
Berry, Richard https://orcid.org/0000-0001-7043-0469
Carrington, Mary https://orcid.org/0000-0002-2692-2180
Altfeld, Marcus https://orcid.org/0000-0001-5972-2997
- License Information
-
More Information
Article History
Received: 13 September 2018
Accepted: 6 June 2019
First Online: 29 July 2019
Competing interests
: A.N., W.F.G.-B. and M.A. filed a patent application (EP18174760.1) regarding the therapeutic use of anti-NKp44 antibodies for the treatment and/or prevention of graft-versus-host disease. M.O. and J.-H.L. are current employees of OneLambda Inc., a part of Thermo Fisher Scientific. All other authors declare no competing interest.
